Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 2015. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibilities (PDMRs), and Connected Persons, filed in accordance with DTR 3.1.4R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share acquisition details.
- Share Price: 1410.76 pence per Share.
- Transaction Date: January 8, 2015.
- Transaction Type: Reinvestment of dividends via the GSK ShareReward Plan.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details specific share acquisitions by the following individuals:
- Directors/PDMRs: Sir Andrew Witty (36 shares), Mr R G Connor (46 shares), Mr S Dingemans (11 shares), Mr S A Hussain (9 shares), Mr D S Redfern (53 shares), Ms C Thomas (53 shares), Mr P C Thomson (26 shares), Dr P J T Vallance (29 shares), Ms E Walmsley (6 shares), Mrs V A Whyte (35 shares).
- Connected Person: Mrs K Thomson (15 shares).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The report is strictly a regulatory disclosure of insider share transactions.
Investor Verification Checklist
- Verify the total number of shares acquired by directors and PDMRs through the ShareReward Plan.
- Confirm the share price of 1410.76 pence per Share on January 8, 2015.
- Review the full list of connected persons involved in the dividend reinvestment.
- Note that this filing contains no financial performance data; refer to Form 20-F for comprehensive financial metrics.